Researchers see promise in generic/4032 combo for melanoma; Biosimilars market to hit $3.7B in 2015;

@FierceBiotech: Which are the best dealmakers in the biopharma business? Item | Follow @FierceBiotech

@JohnCFierce: Tiny San Diego-based Novalar says that it will shut down now that it has sold its only product. Report | Follow @JohnCFierce

> Researchers say that animal studies indicate that the generic arthritis drug leflunomide could be effective against melanoma, especially if it's combined with Plexxikon's closely watched PLX-4032. Story

> Champions Biotechnology has agreed to put its personalized cancer tech to work on two of Cephalon's compounds, snagging a $1.4 million payout and the promise of up to $27 million more. Report

> AstraZeneca's Brilinta, a challenger for the Plavix market, has hit a fresh roadblock in France, where reimbursement regulators are asking for more information. Story

> Israel's Protalix is hatching plans to launch two new clinical programs for drugs that treat Fabry disease and rheumatoid arthritis. The biotech is shooting for new approvals in 2016.  Report

> Some analysts say it's time for a cash-rich Amgen to pay its first dividend. Story

Pharma News

@FiercePharma:  With Sanofi-Merck deal off, look for animal health M&A. Item | Follow @FiercePharma

> Does Steere's exit signal a new day at Pfizer? News

> Judge tosses ex-GSK lawyer's indictment on legal snafu. Article

> FDA lifts fracture warning on OTC stomach meds. Story

> More supply woes as Genzyme scraps Fabrazyme batch. Report

> Bristol chief nabs $10.9M pay package for 2010. News

Vaccines News

> Skipped MMR vaccines lead to oubreak in Minnesota. Item

> Promising protein may yield TB vax. News

> Inovio gets DNA vaccine grant from DoD. Report 

> Novartis gains majority ownership of Zhejiang Tianyuan. Story

Manufacturing News

> FDA steps up counterfeit drug investigations. Story

> KV blinks, but Makena pricing tactic common. Item 

> India sets tone for drug production in Nigeria. Article

> Science uses art tool to ID drug colors. Report

> Fabrazyme falls victim to fill/finish. Story 

> UK pushes continuous manufacturing. News 

And Finally... Datamonitor says that the market for biosimilar drugs will skyrocket from $243 million in 2010 to $3.7 billion by 2015. Story